Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in: The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Biogen CEO Resigns After Six Years of Boom-and-Bust Leadership — Biogen ( BIIB) CEO George Scangos resigned Thursday, the latest and most significant executive exit at the struggling biotech company and a signal that bigger changes may be looming. Scangos will stay on the job for a few months as Biogen's board searches for a successor, according to a statement released by the company in conjunction with second-quarter earnings.

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact — Celgene ( CELG) continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies. Tuesday's deal has Celgene paying $225 million to privately held Jounce Therapeutics to partner on the development of "next generation" cancer immunotherapies.

Bluebird Bio Presents MegaTAL Genome Editing Data At American Society Of Hematology (ASH) Workshop On Genome Editing — bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the presentation of pre-clinical data from its megaTAL genome editing platform at the ASH Workshop on Genome Editing, held July 14-15 in Washington, D.C.

Brainstorm: New ALS Stem Cell Results Support Start of Pivotal Clinical Trial — More patients with amyotrophic lateral sclerosis (ALS) had a positive response to an injection of an experimental stem cell therapy developed by Brainstorm Cell Therapeutics ( BCLI) compared to similar ALS patients given a placebo, according to results from a U.S. clinical trial announced Monday.

Brain Tumor Patient Dies After Ziopharm Gene Therapy Injection — A brain cancer patient died from bleeding in the skull soon after being injected with a Ziopharm Oncology ( ZIOP) gene therapy directly into the brain tumor. The Ziopharm patient, diagnosed with a recurrent brain tumor, was treated with the company's experimental gene therapy, known as Ad-RTS-hIL-12.

XBiotech Colon Cancer Drug Data Deemed Unreliable by European Group — Results from a phase III study of Xylonix, a colon cancer drug developed by XBiotech ( XBIT) , have been deemed unreliable by the European Society of Medical Oncology (ESMO), according to a statement issued Thursday. Serious questions about the XBiotech colon cancer drug were raised after the Xylonix presentation at an ESMO cancer meeting on July 2.

Duchenne Drug Developer (Not Sarepta) Hit with Lengthy FDA Delay — A biotech company developing a Duchenne muscular dystrophy drug has suffered a setback with the U.S. Food and Drug Administration. The company in trouble is Santhera Pharmaceuticals (SANN.SW), not Sarepta Therapeutics ( SRPT) , so breathe. Santhera's timetable to seek approval in the U.S.

Next Up for Celgene's Crohn's Pill: A Snapshot Inside Patients' Colons — Celgene ( CELG) will use a medical meeting this fall to address a lingering investor concern about GED-0301, an experimental pill for Crohn's disease and one of the most important drugs in the company's research pipeline. GED-0301 is one of three drugs -- Otezla and ozanimod are the others -- which form the core of Celgene's burgeoning immunology and inflammation franchise.

ZIOPHARM Announces Plans For Phase I Clinical Trial With CD33 CAR-T Cell Therapy Targeting Acute Myeloid Leukemia — BOSTON, July 12, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced plans for a Phase I adoptive cellular therapy clinical trial utilizing autologous T cells transduced with lentivirus to express a CD33-specific chimeric antigen receptor (CAR) in patients with relapsed or refractory acute myeloid leukemia (AML).

Sage Therapeutics Drug Eliminates Postpartum Depression in Mid-Stage Trial — A lot of people doubted Sage Therapeutics ( SAGE) last summer when the company's experimental drug SAGE-547 erased severe depression in four new mothers diagnosed with postpartum depression. The sample size was too small to draw any real conclusions about the drug, critics said.
More Articles →
Jul 25, 2016

Dear @BostonGlobe -- Stop the Millennium Tower worship. It's tall! It's new! We fucking get it. Enough already! 

Jul 25, 2016

. @JohnCendpts $CELG BD model takes patience but works when you have current products still growing gangbusters. That’s not $GILD today.

Jul 25, 2016

@JohnCendpts To clarify, I meant Milligan has tried to cool investor expectations for a singular, transformative deal.

Jul 25, 2016

@bradloncar @JohnCendpts Nothing new in Milligan’s BD comments tonight. He’s already backed off ONE BIG DEAL in lieu of smaller deals. $GILD

Jul 25, 2016

@RantingMike $GILD always says that about HCV franchise. Not new. It’s a declining franchise. Numbers don’t lie.

Jul 25, 2016

. @sharkbiotech Investor expectations for $GILD Q2 EPS were certainly low but guiding down, even small amount, is a surprise.

Jul 25, 2016

If you were confused about why $MSTX is a penny stock, today’s bullshit EPIC trial delay should straighten you out.

Jul 25, 2016

RT @sharkbiotech: $CELG Remarc study no OS benefit wont seek approval

Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.